Author of

• 10583

  +

  P1.06 - Poster Session 1 - Prognostic and Predictive Biomarkers (ID 161)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10623

    +

    P1.06-040 - The Bim Deletion Polymorphism profile and its relationship with TKIs Resistance in Chinese NSCLC Population (ID 2594)

    09:30 - 09:30  |  Author(s): C. Zhou
    • Abstract

    Background
    Tyrosine kinase inhibitors (TKIs) are widely used in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations. A research recently found that some patients, including NSCLC patients failed their TKI therapy due to a Bim deletion polymorphism. We here try to distinguish the prevalence and clinicopathologic characteristics of the Bim deletion polymorphism in Chinese NSCLC patients.

    Methods
    300 patients were included in the study for Bim polymorphism analysis. PCR and direct sequencing were applied to determine the polymorphism status of tissue or blood sample extracted from these patients. 187 patients who received TKI therapy were further analyzed for relationship between clinicopathologic characteristics, therapeutic effects of TKI and Bim polymorphism status.

    Results
    40 of 300 (13.3%) patients were detected of Bim deletion polymorphism. Further analysis among the 187 patients indicated that this polymorphism distributed randomly in clinical characteristics including age, gender, smoking history, histological type and disease stage. However, patients harboring the Bim polymorphism had significantly shortened progression free survival (PFS) than those without the polymorphism (3.0±1.4 m vs. 7.5±0.9 m, p=0.012). Objective response rate (ORR) in Bim polymorphism carrying patients and wild typed patients also showed significant difference (21.7% vs. 50.6%, p=0.009). In further stratified analysis by EGFR mutation status, the PFS and ORR differences in Bim polymorphism and wild type patients remained significant. Disease control rate (DCR) of the polymorphism carriers also showed a tendency of inferiority (39% vs. 75%, p=0.061), though without a significant difference.

    Conclusion
    Chinese NSCLC patients carrying Bim deletion polymorphism had inferior response to TKI therapy despite EGFR mutation status. And Bim polymorphism could serve as an inferior prognostic factor in NSCLC TKI therapy.